Quick Takeaways
- TLX - Telix Pharmaceuticals Ltd has 7 insiders with reported activity on this page.
- No net insider buy/sell flow is currently reported for the last year.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
Insider Transactions Reported by 7 Insiders of Telix Pharmaceuticals Ltd
- Symbol
- TLX on Nasdaq, TLPPF on OTC
- Location
- North Melbourne, Australia
What Changed
- No meaningful buy/sell imbalance is currently visible in the one-year window.
- Activity will update as new Forms 3/4/5 are filed.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Source Evidence
Filed on Form 4
See Original Filing
Issuer insider activity is sourced from SEC Forms 3, 4, and 5.
Insider trading overview
Last 12 monthsInsider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 23 Apr 2025.
Buys
$0
Shares: 0
Insiders: 0
Sells
$0
Shares: 0
Insiders: 0
Net
$0
Shares: 0
Insiders: 0
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Telix Pharmaceuticals Ltd executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Behrenbruch Christian | MD & Group CEO, Director | $157,386,125 | Mixed | 18 Mar 2026 | ||
| Mr. Mark Nelson | Director | $27,179,337 | Mixed | 18 Mar 2026 | ||
| Ms. Jann Skinner | Director | $4,474,400 | Mixed | 18 Mar 2026 | ||
| David Norman Cade | Group Chief Medical Officer | $2,794,766 | Mixed | 18 Mar 2026 | ||
| Darren Joel Patti | Group Chief Operating Officer | $191,429 | Mixed | 18 Mar 2026 | ||
| Darren Charlton Smith | Group Chief Financial Officer | $89,288 | Mixed | 29 Mar 2026 | ||
| Ms. Marie McDonald | Director | $27,966 | Mixed | 18 Mar 2026 |
Top shareholders of Telix Pharmaceuticals Ltd (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Behrenbruch Christian |
13D/G
3/4/5
|
MD & Group CEO, Director |
7%
|
23,329,006
|
$404,991,544 | $0 | 12 Nov 2024 | |
| Kluge Andreas |
13D/G
|
— |
6.8%
|
22,675,000
|
$393,638,000 | $0 | 12 Nov 2024 | |
| Mr. Mark Nelson |
3/4/5
|
Director |
1.1%
|
3,628,750
|
$27,179,337 | — | 18 Mar 2026 | |
| Ms. Jann Skinner |
3/4/5
|
Director |
0.18%
|
595,000
|
$4,474,400 | — | 18 Mar 2026 | |
| David Norman Cade |
3/4/5
|
Group Chief Medical Officer |
0.11%
|
373,133
|
$2,794,766 | — | 18 Mar 2026 | |
| PORTLAND INVESTMENT COUNSEL INC. |
13F
|
Company |
0.08%
|
266,200
|
$2,063,050 | — | 31 Dec 2025 | |
| LAZARD ASSET MANAGEMENT LLC |
13F
|
Company |
0.07%
|
250,517
|
$1,876,372 | — | 31 Dec 2025 | |
| FMR LLC |
13F
|
Company |
0.04%
|
123,570
|
$925,543 | — | 31 Dec 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.02%
|
74,368
|
$557,016 | — | 31 Dec 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.01%
|
46,658
|
$349,468 | — | 31 Dec 2025 | |
| Private Advisor Group, LLC |
13F
|
Company |
0.01%
|
46,345
|
$347,131 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.01%
|
40,042
|
$299,915 | — | 31 Dec 2025 | |
| Quadrature Capital Ltd |
13F
|
Company |
0.01%
|
36,828
|
$275,842 | — | 31 Dec 2025 | |
| Mariner, LLC |
13F
|
Company |
0.01%
|
36,582
|
$274,001 | — | 31 Dec 2025 | |
| Vident Advisory, LLC |
13F
|
Company |
0.01%
|
27,249
|
$204,095 | — | 31 Dec 2025 | |
| Darren Joel Patti |
3/4/5
|
Group Chief Operating Officer |
—
mixed-class rows
|
26,362
mixed-class rows
|
$191,429 | — | 18 Mar 2026 | |
| IHT Wealth Management, LLC |
13F
|
Company |
0.01%
|
25,285
|
$189,390 | — | 31 Dec 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.01%
|
22,998
|
$172,255 | — | 31 Dec 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.01%
|
19,733
|
$147,800 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.01%
|
18,409
|
$137,883 | — | 31 Dec 2025 | |
| Vanguard Personalized Indexing Management, LLC |
13F
|
Company |
0.01%
|
18,141
|
$135,876 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.01%
|
17,653
|
$132,221 | — | 31 Dec 2025 | |
| OLD MISSION CAPITAL LLC |
13F
|
Company |
0%
|
14,799
|
$110,844 | — | 31 Dec 2025 | |
| Darren Charlton Smith |
3/4/5
|
Group Chief Financial Officer |
0%
|
11,921
|
$89,288 | — | 29 Mar 2026 | |
| XTX Topco Ltd |
13F
|
Company |
0%
|
11,820
|
$88,532 | — | 31 Dec 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0%
|
10,787
|
$80,788 | — | 31 Dec 2025 | |
| Ms. Marie McDonald |
3/4/5
|
Director |
0%
|
3,719
|
$27,966 | — | 18 Mar 2026 | |
| Blue Trust, Inc. |
13F
|
Company |
0%
|
3,086
|
$23,114 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0%
|
1,964
|
$14,710 | — | 31 Dec 2025 | |
| NewEdge Advisors, LLC |
13F
|
Company |
0%
|
1,920
|
$14,381 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0%
|
1,608
|
$12,044 | — | 31 Dec 2025 | |
| BNP PARIBAS FINANCIAL MARKETS |
13F
|
Company |
0%
|
1,500
|
$11,235 | — | 31 Dec 2025 | |
| Arax Advisory Partners |
13F
|
Company |
0%
|
1,083
|
$8,115 | — | 31 Dec 2025 | |
| EverSource Wealth Advisors, LLC |
13F
|
Company |
0%
|
898
|
$6,726 | — | 31 Dec 2025 | |
| Aspect Partners, LLC |
13F
|
Company |
0%
|
352
|
$2,636 | — | 31 Dec 2025 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
314
|
$2,352 | — | 31 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
0%
|
88
|
$659 | — | 31 Dec 2025 | |
| Smartleaf Asset Management LLC |
13F
|
Company |
0%
|
72
|
$558 | — | 31 Dec 2025 | |
| Independence Bank of Kentucky |
13F
|
Company |
0%
|
66
|
$494 | — | 31 Dec 2025 | |
| Cornerstone Financial Management LLC |
13F
|
Company |
0%
|
51
|
$382 | — | 31 Dec 2025 | |
| ASSETMARK, INC |
13F
|
Company |
0%
|
45
|
$337 | — | 31 Dec 2025 | |
| Transamerica Financial Advisors, LLC |
13F
|
Company |
0%
|
25
|
$187 | — | 31 Dec 2025 | |
| Parallel Advisors, LLC |
13F
|
Company |
0%
|
12
|
$93 | — | 31 Dec 2025 | |
| MV CAPITAL MANAGEMENT, INC. |
13F
|
Company |
0%
|
11
|
$83 | — | 31 Dec 2025 | |
| Farther Finance Advisors, LLC |
13F
|
Company |
0%
|
9
|
$67 | — | 31 Dec 2025 | |
| True Wealth Design, LLC |
13F
|
Company |
0%
|
3
|
$23 | — | 31 Dec 2025 | |
| SageView Advisory Group, LLC |
13F
|
Company |
0%
|
2
|
$15 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for Telix Pharmaceuticals Ltd
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Darren Charlton Smith | TLX | Ordinary Shares | Options Exercise | 10.3% | 1,111 | 11,921 | 29 Mar 2026 | Direct | ||
| Darren Charlton Smith | TLX | Share Rights | Options Exercise | -100% | -1,111 | 0 | 29 Mar 2026 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.